Subject to change.
Subject to change.
Dr. Cheng Cui is a regulatory affairs expert with over ten years’ experience across the FDA and industry, specializing in digital health, biomarkers, and oncology diagnostics. At the FDA, he was lead reviewer for digital and computational pathology devices. At AstraZeneca, he leads translational regulatory strategy for AI/ML-enabled computational pathology and biomarkers to advance precision medicine in oncology.